Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1045 results
May 2015
-
Media ReleaseCombination of Novartis drugs Tafinlar® and Mekinist® shows significant survival benefit in patients with metastatic melanomaFinal analysis of COMBI-d confirms overall survival benefit of combination therapy in patients with BRAF V600E/K mutation-positive metastatic melanoma Tafinlar and Mekinist in combination…
-
Media ReleaseNovartis presents new data on 21 medicines and 11 investigational compounds at ASCO and EHAOverall survival data for Tafinlar® and Mekinist® combination to be presented in metastatic BRAF V600E/K mutation-positive cutaneous melanoma New data for Zykadia® in ALK+ non-small cell…
-
Media ReleaseNovartis drug Afinitor® extended progression-free survival in Phase III trial in advanced gastrointestinal or lung neuroendocrine tumorsStudy in patients with advanced nonfunctional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin met primary endpoint[1] Full results will be submitted for presentation at…
-
Media ReleaseNovartis announces two positive US phase III programs in COPD for QVA149 and NVA237QVA149 improved lung function, breathlessness and health-related quality of life in moderate-to-severe COPD patients, according to EXPEDITION trial results[1]-[7] GEM 1 & 2 studies…
-
Media ReleaseNovartis lung cancer drug Zykadia® gains EU approval, providing new therapy for certain patients with ALK+ NSCLCZykadia (ceritinib) is the first treatment option approved for patients in Europe with ALK+ NSCLC previously treated with the ALK inhibitor crizotinib Marketing authorization was based on…
April 2015
-
Media ReleaseNovartis announces Phase III study of Arzerra® met primary endpoint of improved progression-free survival in patients with relapsed CLLPositive top-line results seen with Arzerra plus fludarabine and cyclophosphamide in chronic lymphocytic leukemia (CLL) patients when initial treatment stopped working CLL is the most…
-
Media ReleaseNovartis delivered sales growth (cc), significant margin expansion (cc) and strong innovation in Q1[1]; now with a more focused portfolioContinuing operations[1] saw sales, core[2] operating income and core EPS grow (cc[2]) in Q1 Net sales were USD 11.9 billion (-7%, +3% cc)[2] Operating income was USD 2.8 billion (-1%, +15% cc)…
-
Media ReleaseNovartis celebrates 19th annual Community Partnership Day with more than 27,000 associates volunteering in their local communitiesMore than 27,000 Novartis associates worldwide dedicate an estimated 200,000 hours to volunteer with charitable causes in their communities Community Partnership Day symbolizes the company'…
-
Media ReleaseData at AAN showed Gilenya® high efficacy in achieving 'no evidence of disease activity' in previously-treated highly-active MS patientsNew FREEDOMS/FREEDOMS II sub-group analysis showed Gilenya-treated patients were six-times more likely to achieve 'no evidence of disease activity (NEDA4)' vs placebo NEDA4 is based on four…
-
Media ReleaseSandoz receives FDA approval for GlatopaTM as the first generic competitor to MS therapy Copaxone® 20mgGlatopa is the first FDA-approved, substitutable generic version of Copaxone® 20mg, a treatment for relapsing forms of multiple sclerosis Novartis and Sandoz are driving access to a full…
-
Media ReleaseAlcon receives FDA approval of new multifocal intraocular lens to treat cataract patients in the United StatesUS Food and Drug Administration (FDA) grants approval of the AcrySof® IQ ReSTOR® +2.5 Diopter (D) Intraocular Lens (IOL) for sale in the US Expands Alcon's IOL portfolio for the …
-
Media ReleaseData in The Lancet show Novartis drug Arzerra® plus chlorambucil improved median progression-free survival by 71% in CLL patientsSignificant improvement in PFS seen with Arzerra plus chlorambucil in previously untreated patients with CLL for whom fludarabine-based therapy was inappropriate Chronic lymphocytic…
Pagination
- ‹ Previous page
- 1
- …
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- › Next page